British AI group licenses Janssen drug candidates

British artificial intelligence group BenevolentAI has signed an exclusive license with Johnson & Johnson group Janssen, picking up rights to a series of its novel clinical stage drug candidates.Under the deal, BenevolentAI has acquired a license to a select number of candidates and their extensive related portfolio of patents, after concluding that there is “strong promise” to develop them into new medicines for hard to treat diseases using its artificial intelligence technology. The UK group says the deal will enable it to accelerate its development pipeline and use its unique artificial intelligence technology “to explore and provide a rich source of clinical data”. “The agreement adds further depth to our clinical and preclinical development pipeline and marks a very exciting time for the role of artificial intelligence to benefit scientific…

Link to Full Article: British AI group licenses Janssen drug candidates

Pin It on Pinterest

Share This

Join Our Newsletter

Sign up to our mailing list to receive the latest news and updates about and the Informed.AI Network of AI related websites which includes Events.AI, Neurons.AI, Awards.AI, and Vocation.AI

You have Successfully Subscribed!